- Home
- RXRX vs LU Comparison
RXRX vs LU Comparison
Compare RXRX & LU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RXRX | LU |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RXRX | LU |
|---|---|---|
| Price | $3.80 | $1.65 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $7.50 | $2.00 |
| AVG Volume (30 Days) | ★ 14.2M | 1.1M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $74,681,000.00 | N/A |
| Revenue This Year | $12.11 | N/A |
| Revenue Next Year | $82.52 | $22.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.92 | N/A |
| 52 Week Low | $2.77 | $1.57 |
| 52 Week High | $7.18 | $4.57 |
Technical Indicators
Market Signals| Indicator | RXRX | LU |
|---|---|---|
| Relative Strength Index (RSI) | 65.33 | 35.09 |
| Support Level | $2.85 | $1.57 |
| Resistance Level | $3.99 | $2.77 |
| Average True Range (ATR) | 0.23 | 0.07 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 90.28 | 20.67 |
Price Performance
Historical ComparisonAbout RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
About LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is an investment holding company, together with its consolidated subsidiaries, engaged in core retail credit and enablement business to both borrowers and institutions in the People's Republic of China. The group's segments are Lending-related business, which provides Retail credit and enablement, consumer finance loans, and Digital banking business, including Retail banking and SME banking.